碘对比剂对甲状腺功能影响的研究现状-国家心血管病中心.PDFVIP

中国循环杂志 2015 年 8 月 第 30 卷 第 8 期（总第 206 期）Chinese Circulation Journal，August，2015，Vol. 30 No.8（Serial No.206） 819 stroke progression in patients with acute ischemic stroke and atrial Cardiol, 2010, 56: 1712-1719. fibrillation. Acta Neurol Scand, 2011, 124: 40-44. [35] Latini R, Masson S, Pirelli S, et al. Circulating cardiovascular [30] Marin F, Roldan V, Climent VE, et al. Plasma von Willebrand factor, biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial soluble thrombomodulin, and fibrin D-dimer concentrations in acute fibrillation trial. J Intern Med, 2011, 269: 160-171. onset non-rheumatic atrial fibrillation. Heart, 2004, 90: 1162- 1166. [36] Roldan V, Vilchez JA, Manzano-Fernandez S, et al. Usefulness of [31] Rewiuk K, Wizner B, Fedyk-Lukasik M, et al. Epidemiology and N-terminal pro-B-type natriuretic Peptide levels for stroke risk management of coexisting heart failure and atrial fibrillation in an prediction in anticoagulated patients with atrial fibrillation. Stroke, outpatient setting. Pol Arch Med Wewn, 2011, 121: 392-399. 2014, 45: 696-701. [32] Shin DI, Jaekel K, Schley P, et al. Plasma levels of NT-pro-BNP in [37] Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function patients with atrial fibrillation before and after electrical cardioversion. mutation in familial atrial fibrillation. Science, 2003, 299: 251-254. Z Kardiol, 2005, 94: 795-800. [38] Zhou J, Gao J, Liu Y,et al. Human atrium transcript analysis of [33] Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers permanent atrial fibrillation. Int Heart J,2014,55: 71-77. of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation, 2010, 121: 200-207.